Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study.

Idiopathic normal pressure hydrocephalus Lumboperitoneal shunt Magnetic resonance imaging Outcome Prospective study

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 18 02 2020
accepted: 16 04 2020
revised: 14 04 2020
pubmed: 7 5 2020
medline: 22 6 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

In this prospective, controlled, monocentric study, we described the clinical and neuroimaging 12-month follow-up of two parallel cohorts of subjects with idiopathic normal pressure hydrocephalus (iNPH), who did or did not undergo lumboperitoneal shunt (LPS). We recruited 78 iNPH patients. At baseline, subjects underwent clinical and neuropsychological assessments, 3 T magnetic resonance imaging (MRI), and tap test. After baseline, 44 patients (LPS group) opted for LPS implantation, whereas 34 subjects (control group) declined surgery. Both cohorts were then followed up for 12 months through scheduled clinical and neuropsychological evaluations every 6 months. 3 T MRI was repeated at 12-month follow-up. Gait, balance, and urinary continence improved in the LPS group, without significant influence on cognitive functions. Conversely, gait and urinary continence worsened in the control group. No preoperative MRI parameter was significant outcome predictor after LPS. Of relevance, in responders to LPS, we found postoperative reduction of periventricular white matter (PWM) hyperintensities, which were instead increased in the control group. LPS is safe and effective in iNPH. An early surgical treatment is desirable to prevent clinical worsening. Post-surgery decrease of PWM hyperintensities may be a useful MRI marker surrogate for clinical effectiveness of LPS.

Identifiants

pubmed: 32372182
doi: 10.1007/s00415-020-09844-x
pii: 10.1007/s00415-020-09844-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2556-2566

Subventions

Organisme : Italian Ministry of Health
ID : RF-2013-02355908
Organisme : Health-Service of Lombardy
ID : RF-2013-02355908

Auteurs

Massimiliano Todisco (M)

Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.

Marta Picascia (M)

Alzheimer's Disease Assessment Unit/Laboratory of Neuropsychology, IRCCS Mondino Foundation, Pavia, Italy.

Patrizia Pisano (P)

Neurosurgery Unit, IRCCS San Matteo Foundation, Pavia, Italy.

Roberta Zangaglia (R)

Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.

Brigida Minafra (B)

Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.

Paolo Vitali (P)

Neuroradiology Unit, IRCCS Mondino Foundation, Pavia, Italy.

Elisa Rognone (E)

Neuroradiology Unit, IRCCS Mondino Foundation, Pavia, Italy.

Anna Pichiecchio (A)

Neuroradiology Unit, IRCCS Mondino Foundation, Pavia, Italy.

Roberto Ceravolo (R)

Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Nicola Vanacore (N)

National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.

Alfonso Fasano (A)

Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
Krembil Research Institute, Toronto, ON, Canada.
CenteR for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, ON, Canada.

Claudio Pacchetti (C)

Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy. claudio.pacchetti@mondino.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH